1. Date of Board Report or Resolution: 115/05/08 2. Date of Audit Committee Approval: 115/05/08 3. Reporting Period for Financial Report or Annual Self-Reported Financial Information (Start Date ~ End Date): 115/01/01-115/03/31 4. Cumulative Revenue from Jan 1 to Current Period (Thousand NTD): 34,519 5. Cumulative Gross Profit (or Loss) from Jan 1 to Current Period (Thousand NTD): 12,207 6. Cumulative Operating Income (or Loss) from Jan 1 to Current Period (Thousand NTD): -33,192 7. Cumulative Pre-tax Net Profit (or Loss) from Jan 1 to Current Period (Thousand NTD): -27,091 8. Cumulative Net Profit (or Loss) for the Period from Jan 1 to Current Period (Thousand NTD): -27,091 9. Cumulative Net Profit (or Loss) Attributable to Owners of the Parent Company from Jan 1 to Current Period (Thousand NTD): -15,518 10. Cumulative Basic Earnings Per Share (Loss) from Jan 1 to Current Period (NTD): -0.08 11. Total Assets at End of Period (Thousand NTD): 2,294,540 12. Total Liabilities at End of Period (Thousand NTD): 52,529 13. Equity Attributable to Owners of the Parent Company at End of Period (Thousand NTD): 1,836,172 14. Other Matters to be Notified: None Keywords: Material Information
FACT BOX
- Source: PR Times
- Category: News
- Dates in source: 115/05/08 / 115/01/01-115/03/31
- Products / services: Pharmaceuticals / Biotechnology